Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

Farhad Ravandi, Hagop Kantarjian, Stefan Faderl, Guillermo Garcia-Manero, Susan O'Brien, Charles Koller, Sherry Pierce, Mark Brandt, Deborah Kennedy, Jorge Cortes, Miloslav Beran

Research output: Contribution to journalArticlepeer-review

96 Scopus citations


Mutations of Fms-like tyrosine kinase-3 (FLT3) have been described in about 30% of patients with acute myeloid leukemia (AML) and are associated with a shorter disease-free and overall survival after initial therapy. We sought to examine whether the presence of these mutations in relapsed disease was also associated with a poor response to salvage chemotherapy by comparing the outcome of 34 patients with diploid cytogenetics and mutated FLT3 (internal tandem duplication mutation, ITD) to 69 patients with normal karyotype and wild-type FLT3 (FLT3-WT) in first relapse. On univariate analysis, patients with mutated FLT3 were less likely to achieve a CR to first salvage compared to FLT3-WT patients (24% vs. 41%; P=0.09). Furthermore, survival was longer for the FLT3-WT patients achieving a second CR after salvage compared to FLT3-mutated patients (P=0.017). Overall, patients with mutated FLT3 had a shorter survival from the time of relapse compared to those with FLT3-WT (P<0.001). The adverse prognostic impact of FLT3 mutations appears to persist beyond the initial treatment.

Original languageEnglish (US)
Pages (from-to)752-756
Number of pages5
JournalLeukemia Research
Issue number6
StatePublished - Jun 2010
Externally publishedYes


  • Acute myeloid leukemia
  • FLT3 mutations
  • Outcome
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse'. Together they form a unique fingerprint.

Cite this